GLP-1 (glucagon-like peptide-1) receptor agonists have gained a mass following for their role in managing type 2 diabetes and facilitating weight loss
By conversion of choline to betaine by betaine aldehyde dehydrogenase and choline dehydrogenase [11], the three methyl groups of choline are readily available for three different conversions: (1) sarcosine into glycine by sarcosine dehydrogenase enzyme, (2) by using betaine from betaine-homocysteine methyltransferase as methyl donor and converting homocysteine into methionine, and (3) in conversion of dimethylglycine into sarcosine by dimethylglycine dehydrogenase enzyme
This information should be interpreted with your qualified healthcare provider to inform which delivery method and dosing strategy may align with your physiology
This customization may make it a worthwhile investment, as personalized treatment plans often yield better results
To qualify, you need Part D drug coverage and you need to hit one of the following thresholds: Have a BMI of 35 or higher Have a BMI of 30 or higher with heart failure with preserved ejection fraction, uncontrolled high blood pressure or chronic kidney disease at stage 3a or higher Have a BMI of 27 or higher with prediabetes, or a prior heart attack, stroke or blocked arteries in the legs or arms If you're already getting GLP-1 coverage through Medicare for type 2 diabetes, sleep apnea or a fatty liver disease called MASH, the Bridge program doesn't apply to you you're already covered through a different channel
PlexusDx makes semaglutide injection accessible at $189/mo (or $149/mo on the 6-month plan) with no insurance required, eliminating cost as a reason to delay starting your health transformation
